scholarly journals From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation

2017 ◽  
Vol 4 (6) ◽  
pp. 39-39 ◽  
Author(s):  
Roni Shouval ◽  
Arnon Nagler
Keyword(s):  
Risk Factors ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Outcome Prediction ◽  
Cord Blood Transplantation ◽  
Prognostic Models ◽  
Umbilical Cord Blood Transplantation ◽  
Patient Centered ◽  
Blood Transplantation

Incidence and risk factors of food allergy after umbilical cord blood transplantation in children

2017 ◽  
Vol 5 (6) ◽  
pp. 1789-1791 ◽  
Author(s):  
Alfonso Hernández-Ojeda ◽  
Nicolás Rojas ◽  
Francisco Barriga ◽  
María Angélica Wietstruck ◽  
Pamela S. Morales ◽  
...  
Keyword(s):  
Risk Factors ◽  
Food Allergy ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Cord Blood Transplantation ◽  
Umbilical Cord Blood Transplantation ◽  
Blood Transplantation

CMV Infection Alone Does Not Affect The Survival In Patients After Umbilical Cord Blood Transplantation: Can We Put Off The Time Of Preemptive Therapy?

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5458-5458
Author(s):  
Juan Tong ◽  
Zimin Sun ◽  
Huilan Liu ◽  
Kaiyang Ding ◽  
Liangquan Geng ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Cord Blood Transplantation ◽  
Preemptive Therapy ◽  
Umbilical Cord Blood Transplantation ◽  
Cmv Infection ◽  
Blood Transplantation ◽  
Cmv Disease

Abstract Objective Analysis and discuss the time of cytomegalovirus (CMV) preemptive therapy after umbilical cord blood transplantation (UCBT). Analysis the risk factors of CMV infection and the effect on survival of CMV infection after UCBT. Method From April 2000 to March 2013, 176 cases of patients undergo UCBT who were detected plasma CMV-DNA twice a week routinely. Preemptive antiviral therapy was initiated with ganciclovir or foscarnet for positive PCR of 103 DNA copies or more per ml. Results 125 of 176 patients developed CMV infection (71%) at a median of 32d (range 19 to 98) post-transplant and only 4 patients developed CMV disease (2.3%). The 5-year overall (OS) was 59.4% in the patients with CMV infection and 64.9% in patients without CMV infection (P=0.193). The study identified that younger age, high-risk disease, infused little CD34 positive cells, developed III-IV degree acute graft-versus-host disease (GVHD), high-dose methylprednisolone, and treated with basiliximab and other strong immunosuppressive agent as significant risk factors for developing CMV infection. It had nothing to do with the gender of patients, transplantation of UCB units, the conditioning regime, the day of neutrophil recovery and chronic GVHD. Preemptive therapy when the CMV-DNA copies are greater than 103 does not increase the incidence of CMV disease, and the survival has not been impacted. Conclusion Preemptive therapy can be initiated when CMV-DNA copies are greater than 103 which can achieve the same effects in UCBT. Disclosures: No relevant conflicts of interest to declare.

Pre-Engraftment Syndrome Following Umbilical Cord Blood Transplantation Is a Strong Predictor of Acute Graft-Versus-Host Disease

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1267-1267
Author(s):  
Xingbing Wang ◽  
Zimin Sun ◽  
Huilan Liu ◽  
Liangquan Geng ◽  
Kaiyang Ding ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Research Funding ◽  
Cord Blood Transplantation ◽  
Umbilical Cord Blood Transplantation ◽  
Neutrophil Recovery ◽  
Blood Transplantation ◽  
Engraftment Syndrome

Abstract Abstract 1267 Pre-engraftment syndrome (PES) has been described in patients receiving umbilical cord blood transplantation (CBT). However, PES remains poorly characterized, and the prognosis and appropriate management are unclear. Therefore, we retrospectively analyzed the incidence, risk factors, manifestations, and clinical outcome of PES in CBT recipients treated for hematological malignancies at our transplantation center. A total of 60 patients (median 20 years, range 3–48) received either myeloablative (n=52) or reduced-intensity (n=8) conditioning. 28 patients received double unit grafts to augment engraftment. Cyclosporine-A and mycophenolate mofetil were used as GVHD prophylaxis, and all patients received post-transplant granulocyte colony-stimulating factor. In this study, PES was defined as noninfectious fever (>38.3°C) and/or unexplained rash occurring before neutrophil engraftment. 38 patients (63.3%) fulfilled PES criteria: 33 with fever and 36 with rash. The median onset was 8 days (range 3–15) post-transplant (a median of 12 days before neutrophil recovery). 34 patients received IV methylprednisolone (MP) (0.5-2 mg/kg/d) with 27/34 (79.4%) having fever and/or rash resolution in <48 hours. Univariate analysis identified myeloablative conditioning and younger age as significant risk factors for developing PES. Use of TBI or ATG in conditioning regimen, the infused total nucleated cell dose, gender, weight, blood type mismatch, transplantation of UCB units and degree of donor-recipient HLA disparity were not significantly associated with the development of PES in our series. The cumulative incidence of sustained donor engraftment was 83.3%. Patients with PES had a higher incidence of developing grade II -IV acute GVHD, but PES was not associated with sustained donor engraftment, the day to neutrophil recovery and chronic GVHD. Overall survival did not significantly differ between patients with and without PES. We conclude that PES is common following CB transplant (CBT), predicts for aGVHD, and responds promptly to corticosteroids. Disclosures: Wang: Fund of the Key Medical Project of Anhui Provincial healthy department (2010A005): Research Funding; Clinical Technology foundation of Anhui Provincial healthy department (2008A011): Research Funding; Fund of Anhui Provincial “115” Industrial Innovation Program: Research Funding; Anhui Provincial Outstanding Young Investigator Program (08040106810): Research Funding.

Intrabone infusion for allogeneic umbilical cord blood transplantation in children

2021 ◽  
Author(s):  
Stephanie Vairy ◽  
Isabelle Louis ◽  
Marie-France Vachon ◽  
Johanne Richer ◽  
Pierre Teira ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Cord Blood Transplantation ◽  
Umbilical Cord Blood Transplantation ◽  
Blood Transplantation
Sign in / Sign up

Export Citation Format

Share Document